ADARx Pharmaceuticals
Company Type: Therapeutic development
Main focus: Developing novel treatments for several genetic, cardiometabolic, and central nervous system diseases through RNA targeting
Company stage: Clinical
Diseases: Various genetic, cardiometabolic, complement-mediated, and central nervous system diseases
Genome-editing tool: RNA editing
Funding stage: Series C
Location: San Diego, California, USA
Website: https://www.adarx.com/
Pipeline: www.adarx.com/our-technology/
Partners:
ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on developing RNA-targeting therapeutics. The company utilises proprietary oligonucleotide technologies for RNA inhibition, degradation, and editing, along with delivery systems including the PLR™ (Preeminent Liver RNA) platform and SPE™ (Sequence Specific Platform Enhancement) technology. ADARx's pipeline includes treatments for genetic, cardiometabolic, complement-mediated, and central nervous system diseases.